The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.

@article{Kharitonenkov2007TheMS,
  title={The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.},
  author={A. Kharitonenkov and V. Wroblewski and A. Koester and Y. Chen and Cathleen K Clutinger and X. Tigno and B. Hansen and A. Shanafelt and G. Etgen},
  journal={Endocrinology},
  year={2007},
  volume={148 2},
  pages={
          774-81
        }
}
Fibroblast growth factor (FGF)-21 has been recently characterized as a potent metabolic regulator. Systemic administration of FGF-21 reduced plasma glucose and triglycerides to near normal levels in genetically compromised diabetic rodents. Importantly, these effects were durable and did not come at the expense of weight gain, hypoglycemia, or mitogenicity. To explore the therapeutic properties of FGF-21 in a nongenetically modified primate species, and thus demonstrate the potential for… Expand
Increased fibroblast growth factor 21 expression in high-fat diet-sensitive non-human primates (Macaca mulatta)
TLDR
This study demonstrates that HFD changes FGF 21 and FGF21 receptor expression in a tissue-specific manner in rhesus monkeys; differential regulation is moreover observed between HFD-sensitive and -resistant monkeys. Expand
Fibroblast Growth Factor 21 as an emerging metabolic regulator: clinical perspectives
TLDR
High circulating FGF21 levels are found in obesity and its related cardiometabolic disorders including the metabolic syndrome, type 2 diabetes, non‐alcoholic fatty liver disease and coronary artery disease, and imply the need for supraphysiological doses of FGF 21 to achieve therapeutic efficacy. Expand
Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21.
TLDR
FGF21 is a recently identified hormone with antihyperglycemic, antihyperlipidemic, and thermogenic properties and might be a potential therapeutic target in insulin-resistant states. Expand
LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys
TLDR
The pharmacologic outcomes observed in non-human primates upon administration of a recently described FGF21 analogue, LY2405319 (LY), show that FGF 21 based therapy has metabolic efficacy in an animal with late stage diabetes and support continued exploration of the F GF21 pathway for the treatment of metabolic disease. Expand
Decreased levels of Fibroblast Growth Factor 21 are correlated with improved hypoglycemia in patients with insulinoma
TLDR
Interestingly, it was found that the serum FGF21 levels increased significantly in patients with insulinoma at baseline compared with the control group, and its change was still correlated positively with the changes in insulin and proinsulin after surgery. Expand
Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice.
TLDR
An improvement in insulin responsiveness in FGF21-treated HFD-fed mice was associated with decreased hepatocellular and myocellular diacylglycerol content and reduced protein kinase Cε activation in liver and protein kinases Cθ in skeletal muscle, and there were no effects of FGF 21 on liver or muscle ceramide content. Expand
Fibroblast growth factor 21 corrects obesity in mice.
TLDR
It is reported that systemic administration of FGF21 for 2 wk in diet-induced obese and ob/ob mice lowered their mean body weight by 20% predominantly via a reduction in adiposity. Expand
Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
TLDR
The response of obese mice to exogenous FGF21 administration is evaluated to test the hypothesis that obesity is a state of FGF 21 resistance and demonstrate that DIO mice have increased endogenous levels of F GF21 and respond poorly to exogeneity. Expand
Fibroblast growth factor 21: effects on carbohydrate and lipid metabolism in health and disease
TLDR
A review of recent findings examining the effects of fibroblast growth factor (FGF) 21 on carbohydrate and lipid metabolism with emphasis on publications from 2010 suggests obesity as a FGF21-resistant state. Expand
Fibroblast growth factor-21: A link for glucose homeostasis
TLDR
Treatment of type II diabetic patients who present typical insulin resistance with functional pancreatic function may benefit from FGF-21 therapy, as pre-clinical and clinical studies have indicated remarkably potent effects of F GF-21 on plasma lipid profile and reduction of plasma glucose levels. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 31 REFERENCES
FGF-21 as a novel metabolic regulator.
TLDR
It is concluded that FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes. Expand
Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity.
TLDR
It is reported that FGF19 transgenic mice had a significant and specific reduction in fat mass that resulted from an increase in energy expenditure and did not become obese or diabetic on a high fat diet. Expand
Fibroblast Growth Factor-21 Improves Pancreatic β-Cell Function and Survival by Activation of Extracellular Signal–Regulated Kinase 1/2 and Akt Signaling Pathways
TLDR
Preservation of β-cell function and survival by FGF-21 may contribute to the beneficial effects of this protein on glucose homeostasis observed in diabetic animals. Expand
Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes.
TLDR
Treatment with FGF19 prevented or reversed the diabetes that develops in mice made obese by genetic ablation of brown adipose tissue or genetic absence of leptin, and profiled the F GF19-induced gene expression changes in the liver and brown fat. Expand
Biochemical and morphological effects of K-111, a peroxisome proliferator-activated receptor (PPAR)α activator, in non-human primates
TLDR
K-111 is a highly promising drug candidate for clinical applications in the treatment of type 2 diabetes, dyslipidaemia, obesity and the metabolic syndrome and corresponds to the observations with fibrates in other low responder mammalian species. Expand
Effects of fenofibrate on lipid parameters in obese rhesus monkeys.
TLDR
The use of obese rhesus monkey as an excellent animal model for studying the effects of novel hypolipidemic agents, particularly agents that impact serum triglycerides and HDL-C, is supported. Expand
A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport
  • W. Oliver, J. Shenk, +12 authors T. Willson
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 2001
TLDR
The results suggest that PPARδ agonists may be effective drugs to increase reverse cholesterol transport and decrease cardiovascular disease associated with the metabolic syndrome X. Expand
Endogenous glucose production is inhibited by the adipose-derived protein Acrp30.
TLDR
Results indicate that an acute increase in circulating Acrp30 levels lowers hepatic glucose production without affecting peripheral glucose uptake, and a moderate rise in circulating levels of the adipose-derived protein Acp30 inhibits both the expression of hepatic gluconeogenic enzymes and the rate of endogenous glucose production. Expand
Recent findings concerning thiazolidinediones in the treatment of diabetes
TLDR
Because PPar-α and -γ agonists improve atherosclerotic vascular disease and insulin sensitivity, respectively, dual PPAR-α/γ agonist may be useful in treating patients with the metabolic syndrome. Expand
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis.
TLDR
It is demonstrated that fibroblast growth factor 15 signals from intestine to liver to repress the gene encoding cholesterol 7alpha-hydroxylase (CYP7A1), which catalyzes the first and rate-limiting step in the classical bile acid synthetic pathway. Expand
...
1
2
3
4
...